Skip to content

Investors & Media


Data Provided by Refinitiv.
Minimum 15 minutes delayed.

lnk Stock Information

Learn More

Creating value by saving sight through transformative science.

Press Releases

05-May-21

Graybug Vision to Report Full-Data Analysis of the 12-month Treatment Phase of its Phase 2b ALTISSIMO Trial

REDWOOD CITY, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced it will host a conference call and

09-Mar-21

Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial

Median time to first supportive therapy was 5 months for GB-102 1mg 48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 months Control of retinal thickness was consistent across all trial arms Mean best-corrected visual acuity with GB-102 1mg trended lower than aflibercept arm No

04-Mar-21

Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate

lnk News

View All News

Connect with Us
Sign up for ongoing news and events.
Font Resize